Beone Medicines Ltd (ONC) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
Beone Medicines Ltd   (NASDAQ: ONC)

Select the Financial Report: Select the Period:


Description of Beone Medicines Ltd's Business Segments
The company operates a single reportable segment focused on pharmaceutical products. The Chief Executive Officer reviews consolidated results for resource allocation and performance evaluation of the company as a whole.

Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Composition of Beone Medicines Ltd Revenues by Segments
 
Other Revenue    1.73 % of total Revenue
Other Revenue Novartis    1.73 % of total Revenue
Amgen royalty revenue Novartis    1.21 % of total Revenue
Novartis broad markets revenue Novartis    0.35 % of total Revenue
Other Novartis    0.17 % of total Revenue
Product revenue    98.29 % of total Revenue
Product revenue BRUKINSA    72.35 % of total Revenue
Product revenue TEVIMBRA    13.63 % of total Revenue
Product revenue XGEVA    5.94 % of total Revenue
Product revenue BLINCYTO    2.25 % of total Revenue
Product revenue KYPROLIS    1.12 % of total Revenue
Product revenue POBEVCY    0.8 % of total Revenue
Product revenue Other    2.19 % of total Revenue
U S - total revenue    51.69 % of total Revenue
China - total revenue    31.19 % of total Revenue
Europe - total revenue    12.82 % of total Revenue
Rest of world - total revenue    4.31 % of total Revenue
Product revenue U S - total revenue    50.59 % of total Revenue
Product revenue China - total revenue    30.74 % of total Revenue
Product revenue Europe - total revenue    12.64 % of total Revenue
Product revenue Rest of world - total revenue    4.31 % of total Revenue
Other Revenue U S - total revenue    1.1 % of total Revenue
Other Revenue China - total revenue    0.45 % of total Revenue
Other Revenue Europe - total revenue    0.18 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)		 %
(of total Revenues)
Other Revenue 26.11 1.73 %
Other Revenue Novartis 26.11 1.73 %
Amgen royalty revenue Novartis 18.30 1.21 %
Novartis broad markets revenue Novartis 5.26 0.35 %
Other Novartis 2.55 0.17 %
Product revenue 1,487.33 98.29 %
Product revenue BRUKINSA 1,094.84 72.35 %
Product revenue TEVIMBRA 206.24 13.63 %
Product revenue XGEVA 89.92 5.94 %
Product revenue BLINCYTO 34.04 2.25 %
Product revenue KYPROLIS 16.97 1.12 %
Product revenue POBEVCY 12.13 0.8 %
Product revenue Other 33.19 2.19 %
U S - total revenue 782.26 51.69 %
China - total revenue 471.97 31.19 %
Europe - total revenue 194.00 12.82 %
Rest of world - total revenue 65.21 4.31 %
Product revenue U S - total revenue 765.61 50.59 %
Product revenue China - total revenue 465.18 30.74 %
Product revenue Europe - total revenue 191.32 12.64 %
Product revenue Rest of world - total revenue 65.21 4.31 %
Other Revenue U S - total revenue 16.64 1.1 %
Other Revenue China - total revenue 6.79 0.45 %
Other Revenue Europe - total revenue 2.68 0.18 %
Total 1,513.22 100 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%		 Q/Q Revenue
%
Other Revenue 198.42 % -
Other Revenue Novartis 198.42 % -
Amgen royalty revenue Novartis 231.53 % -
Novartis broad markets revenue Novartis 49.43 % -
Other Novartis - -
Product revenue 34.17 % -
Product revenue BRUKINSA 38.3 % -
Product revenue TEVIMBRA 20.49 % -
Product revenue XGEVA 27.69 % -
Product revenue BLINCYTO 42.37 % -
Product revenue KYPROLIS -13.98 % -
Product revenue POBEVCY -11.77 % -
Product revenue Other 85.43 % -
U S - total revenue 37.91 % -
China - total revenue 18.11 % -
Europe - total revenue 63.64 % -
Rest of world - total revenue 104.29 % -
Product revenue U S - total revenue 35.9 % -
Product revenue China - total revenue 17.36 % -
Product revenue Europe - total revenue 63.66 % -
Product revenue Rest of world - total revenue 104.29 % -
Other Revenue U S - total revenue 330.81 % -
Other Revenue China - total revenue 110.28 % -
Other Revenue Europe - total revenue 61.53 % -
Total 35.44 % -71.68 %




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)		 %
(Profit Margin)
Total 227.36 15.02 %




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%		 Q/Q Income
%
Total 17802.13 % -20.76 %




Annual Report on Beone Medicines Ltd Divisions, Sales by Country

 
Amgen royalty revenue Novartis   Amgen royalty revenue Novartis Segment contribution to total sales 0.76 % of total Revenue
Novartis broad markets revenue Novartis   Novartis broad markets revenue Novartis Segment contribution to total sales 0.33 % of total Revenue
Other Novartis   Other Novartis Segment contribution to total sales 0.05 % of total Revenue
U S - total revenue   U S - total revenue Segment contribution to total sales 53.91 % of total Revenue
Other revenue   Other revenue Segment contribution to total sales 1.14 % of total Revenue
Other revenue Novartis   Other revenue Novartis Segment contribution to total sales 1.14 % of total Revenue
Other revenue Ociperlimab   Other revenue Ociperlimab Segment contribution to total sales 0.33 % of total Revenue
Other Ociperlimab   Other Ociperlimab Segment contribution to total sales 0.33 % of total Revenue
Product revenue net   Product revenue net Segment contribution to total sales 98.87 % of total Revenue
Product revenue net BRUKINSA   Product revenue net BRUKINSA Segment contribution to total sales 73.53 % of total Revenue
Product revenue net TEVIMBRA   Product revenue net TEVIMBRA Segment contribution to total sales 13.8 % of total Revenue
Product revenue net XGEVA   Product revenue net XGEVA Segment contribution to total sales 5.73 % of total Revenue
Product revenue net BLINCYTO   Product revenue net BLINCYTO Segment contribution to total sales 1.95 % of total Revenue
Product revenue net KYPROLIS   Product revenue net KYPROLIS Segment contribution to total sales 1.4 % of total Revenue
Product revenue net POBEVCY   Product revenue net POBEVCY Segment contribution to total sales 0.89 % of total Revenue
Product revenue net Other   Product revenue net Other Segment contribution to total sales 1.57 % of total Revenue
Rebates Returns and Other Deductions   Rebates Returns and Other Deductions Segment contribution to total sales 12.3 % of total Revenue
Contra AR Accruals   Contra AR Accruals Segment contribution to total sales 14.82 % of total Revenue
U S - total revenue Product revenue net   U S - total revenue Product revenue net Segment contribution to total sales 53.18 % of total Revenue
U S - total revenue Other revenue   U S - total revenue Other revenue Segment contribution to total sales 0.73 % of total Revenue
China- total revenue   China- total revenue Segment contribution to total sales 31.44 % of total Revenue
China- total revenue Product revenue net   China- total revenue Product revenue net Segment contribution to total sales 31.06 % of total Revenue
China- total revenue Other revenue   China- total revenue Other revenue Segment contribution to total sales 0.38 % of total Revenue
Europe- total revenue   Europe- total revenue Segment contribution to total sales 11.44 % of total Revenue
Europe- total revenue Product revenue net   Europe- total revenue Product revenue net Segment contribution to total sales 11.41 % of total Revenue
Europe- total revenue Other revenue   Europe- total revenue Other revenue Segment contribution to total sales 0.03 % of total Revenue
Rest of world- total revenue   Rest of world- total revenue Segment contribution to total sales 3.22 % of total Revenue
Rest of world- total revenue Product revenue net   Rest of world- total revenue Product revenue net Segment contribution to total sales 3.22 % of total Revenue


Twelve months ended 2025
ONC s Annual Revenue by Geography and Business Segments Sales
(in millions $)		 %
(of total Sales)
Amgen royalty revenue Novartis 40.73 0.76 %
Novartis broad markets revenue Novartis 17.60 0.33 %
Other Novartis 2.64 0.05 %
U S - total revenue 2,880.32 53.91 %
Total 5,342.49 100 %
Other revenue 60.97 1.14 %
Other revenue Novartis 60.97 1.14 %
Other revenue Ociperlimab 17.60 0.33 %
Other Ociperlimab 17.60 0.33 %
Product revenue net 5,282.06 98.87 %
Product revenue net BRUKINSA 3,928.49 73.53 %
Product revenue net TEVIMBRA 737.30 13.8 %
Product revenue net XGEVA 305.98 5.73 %
Product revenue net BLINCYTO 104.22 1.95 %
Product revenue net KYPROLIS 74.97 1.4 %
Product revenue net POBEVCY 47.40 0.89 %
Product revenue net Other 83.69 1.57 %
Rebates Returns and Other Deductions 657.14 12.3 %
Contra AR Accruals 791.76 14.82 %
U S - total revenue Product revenue net 2,841.25 53.18 %
U S - total revenue Other revenue 39.08 0.73 %
China- total revenue 1,679.53 31.44 %
China- total revenue Product revenue net 1,659.36 31.06 %
China- total revenue Other revenue 20.17 0.38 %
Europe- total revenue 611.37 11.44 %
Europe- total revenue Product revenue net 609.64 11.41 %
Europe- total revenue Other revenue 1.73 0.03 %
Rest of world- total revenue 171.81 3.22 %
Rest of world- total revenue Product revenue net 171.81 3.22 %


Twelve months ended 2025
ONC s Annual Income by Country and Business Segments Income
(in millions $)		 %
(Profit Margin)
Total 286.93 5.37 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Amgen royalty revenue Novartis 419.49 % -
Novartis broad markets revenue Novartis -3.62 % -
Other Novartis -42.52 % -
U S - total revenue 47.14 % -
Total 40.22 % -
Collaboration revenue - -
Other revenue 98.64 % -
Other revenue Novartis 98.64 % -
Other revenue Ociperlimab -3.62 % -
Other Ociperlimab -3.62 % -
Product revenue net 39.75 % -
Product revenue net BRUKINSA 48.57 % -
Product revenue net TEVIMBRA 18.76 % -
Product revenue net XGEVA 36.35 % -
Product revenue net BLINCYTO 40.22 % -
Product revenue net KYPROLIS 13.3 % -
Product revenue net POBEVCY -11.42 % -
Product revenue net Other -12.89 % -
Rebates Returns and Other Deductions 33.63 % -
Contra AR Accruals 53.61 % -
U S - total revenue Product revenue net 45.67 % -
U S - total revenue Other revenue 460.82 % -
China- total revenue 19.01 % -
China- total revenue Product revenue net 19.32 % -
China- total revenue Other revenue -2.14 % -
Europe- total revenue 68.59 % -
Europe- total revenue Product revenue net 69.58 % -
Europe- total revenue Other revenue -44.66 % -
Rest of world- total revenue 118 % -
Rest of world- total revenue Product revenue net 118 % -
Collaboration revenue Novartis - -
Collaboration revenue Tislelizumab - -
Collaboration revenue Ociperlimab - -
Other Tislelizumab - -
Product revenue net Tislelizumab - -
Product revenue net REVLIMID - -
U S - total revenue Collaboration revenue - -
China- total revenue Collaboration revenue - -
Europe- total revenue Collaboration revenue - -
Other revenue TEVIMBRA - -
Other TEVIMBRA - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.